Purpura Fulminans is a topic covered in the Select 5-Minute Pediatrics Topics.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Hematologic emergency characterized by dermal hemorrhagic necrosis and disseminated intravascular coagulation (DIC)
  • Associated with a congenital or acquired protein C and/or protein S deficiency
  • Life-threatening condition that requires prompt diagnosis and judicious replacement therapy to decrease morbidity and mortality

Epidemiology

  • Neonatal purpura fulminans related to homozygous protein C deficiency: 1 in 2–4 million births
  • Clinical protein C deficiency: 1 in 20,000 individuals
  • Homozygous protein S deficiency is exceptionally rare.
  • Predicted prevalence of severe protein C deficiency is 1 in 40,000–250,000 individuals. Significantly less seen in practice, likely due to associated high rate of fetal loss and perinatal mortality

Risk Factors

Genetics

  • Deficiencies of protein C and protein S are autosomally inherited with variable penetrance.
  • Over 150 different genetic mutations of protein C have been described, leading to both qualitative and quantitative defects of the proteins.
  • Homozygous protein C or S deficiency and compound heterozygous states are associated with severe deficiency, <1% normal activity level.
  • Neonatal purpura fulminans is associated with a severe protein C or S deficiency.
  • Coinheritance with other thrombophilias may also contribute to the risk of developing purpura fulminans.
  • Heterozygous protein C and S deficiency are associated with a lifetime increased risk of venous and arterial thrombosis.

Pathophysiology

Common features of purpura fulminans:

  • DIC: Endothelial injury from bacterial endotoxin or other trigger may initiate secretion of inflammatory cytokines or activation of coagulation and complement proteins.
  • Purpura: due to perivascular hemorrhage
  • Dermal vascular thrombosis: formation of microthrombosis in blood vessels of the skin, leading to hemorrhage in the skin (purpura), necrosis of skin, and gangrene

Etiology

  • Acquired causes:
    • Severe acute bacterial infections: Neisseria meningitidis most common
    • Postinfectious fulminans: most commonly associated with varicella and Streptococcus infections. Caused by cross-reacting IgG antibodies that increase protein S clearance from the circulation. Consider in an otherwise well child with new-onset purpura fulminans and DIC.
    • Warfarin (Coumadin)-induced skin necrosis
    • DIC
    • Antiphospholipid antibodies
    • Cardiac bypass
    • Severe liver dysfunction
    • Galactosemia
    • Severe congenital heart disease
  • Inherited protein C pathway defects
    • Predisposes to a reduced capacity to inhibit thrombin formation and therefore a hypercoagulable state
  • Inherited defect of coagulation presenting as neonatal purpura fulminans
    • Protein C slows (“brakes”) the coagulation cascade at two steps: by degrading activated factor V and activated factor VIII.
    • Also plays a role in inflammatory cascade
    • Protein S is a cofactor for protein C.

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Purpura Fulminans ID - 14037 Y1 - 2015 PB - Select 5-Minute Pediatrics Topics UR - https://im.unboundmedicine.com/medicine/view/Select-5-Minute-Pediatric-Consult/14037/all/Purpura_Fulminans ER -